Upload
jeri
View
23
Download
0
Embed Size (px)
DESCRIPTION
Increasing Biotech Involvement in Global Health Innovation. Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007 James A. Geraghty Genzyme Corporation. Objectives of today’s talk. Provide rationale/mandate for involvement - PowerPoint PPT Presentation
Citation preview
1
Increasing Biotech Involvement in Global Health Innovation
Oxford Conference on Innovation and Technology Transfer for Global Health
September 11, 2007
James A. Geraghty
Genzyme Corporation
2
Objectives of today’s talk
Provide rationale/mandate for involvement
Outline possible approaches and contributions
Summarize one company’s involvement
Catalyze discussion and new initiatives
3
The Case for Corporate Involvement
To maintain policy support – regulatory, pricing, IP … To maintain long-term public trust and goodwill To attract and retain highly motivated employees To develop relationships in emerging markets To develop new capabilities through partnerships
Many agree – why isn’t more done?
Not charity- a strategic responsibility
4
(Perceived) Barriers to Involvement
“We’re not experts in these diseases”
“We can’t afford the expenses”
“It’s not in our shareholders’ interest”
“We’ll only spark more criticism”
5
Twin Pillars of Partnership
Access CriteriaIndustry Needs
Guiding Principles:
• Maximize access: developing countries
• Minimize costs: prices, royalties
• Make IP available: PPO’s, NGO’s, Governments
Sustainability:
• Offset R&D costs: funding, tax credits
• Provide markets: AMC’s, developed world
• Policy support: reimbursement, IP, etc
6
Potential Biotech Contributions
Products Capabilities
Some Companies
All Companies
7
One Company’s Approach Seek out leaders in the field
Focus on ways we can add value
Provide IP in “field” to non-profit partner
Retain IP rights, if any, outside “field”
Start small and work with funders to grow
8
Genzyme/DNDi Partnership: African Tryps
Identify novel inhibitors of polyamine biosynthesis
Genzyme Compounds impacting polyamine metabolism and other pathways Synthetic medicinal chemistry and pharmaceutical development
DNDI Expertise in disease biology In vitro and in vivo testing Resources, network and infrastructure to execute clinical trials
One lead has shown superior results; optimization on going
9
Genzyme/Broad/MMV Partnership: Malaria
Goal: Sustainable pipeline of novel clinical candidates
Exploit existing drug candidates and screens
Utilize new genomic database to identify novel targets
Develop chemical genetics screens to validate targets
Support partners in conducting clinical trials
10
Conclusions
Perceived barriers act as real barriers
Perceptions can reflect an obsolete environment
Solutions to the real problems are not easy
The future belongs to those who see opportunities